Acknowledgements

This exhibition was put together with the kind support of those who were involved in the creation of alemtuzumab and includes many of the original documents and photographs collected during its development. Without the support and encouragement of these people, this exhibition would not have been possible. Warm thanks also go to the many patients who were willing to share their experiences for the exhibition. Material was generously donated by the following:

The individuals listed above not only contributed original documents for this exhibition, but gave up their time to give extensive interviews. All the evidence provided by these different people offers a rich and powerful testimony of the risks and benefits involved in biotechnology drugs and serves as a reminder of the importance of scientists, physicians, patients, industry and government bodies all pulling together in the development of biotechnology for improving healthcare.

Research for this exhibition was aided by funding from Clark Antibodies Ltd, Geoff Hale and the Medical Research Council.

Some of the photographs of patients included in this exhibition were taken by Millie Brierley for the exhibition called “Care at the Leading Edge”, 1999. Writing of the exhibition Millie states:

I shall always remember all the patients and their families who allowed me to photograph them and who thoughtfully recounted their experiences to me. My admiration for their bravery, tenacity and positive attitudes was overwhelming – to be photographed when feeling unwell must take very special strength! I met lots of wonderful people while working on this project and I will never forget their generous hospitality and friendship towards me...Through collaboration with individual patients, I aimed to communicate, using image and text, many of the problems which patients encountered before, during and following treatment. The central issues included: years of incorrect diagnosis, isolation, and the effects of illness on personal relationships...I will never forget Dr Martin Lockwood, who entrusted me with this important, challenging commission in 1999. The project took nearly nine months to complete and Martin was always ready to listen, care and enthusiastically discuss and respond to work in progress. He was an inspiration to all his patients and to me.

Please note This exhibition's content is limited to the sources collected from people who were available during the construction of the exhibition. It does not capture the multiple stories of the many other people who were involved in the making of the drug. Comments and material are welcome from anyone who was involved in the development the alemtuzumab which has not been captured in this exhibition. Any contributions should be sent to editorial@whatisbiotechnology.org.

Follow us to keep up with all the new content about the world of biotechnology.